Mitsuyoshi Urashima

Prof. Mitsuyoshi Urashima

Division of Molecular Epidemiology, Jikei University School of Medicine, Tokyo, Japan
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2010 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
Mitsuyoshi UrashimaMitsuyoshi Urashima
Mitsuyoshi Urashima
TSTakaaki Segawa
Takaaki Segawa
MOMinoru Okazaki
Minoru Okazaki
MKMana Kurihara
Mana Kurihara
YWYasuyuki Wada
Yasuyuki Wada
HIHiroyuki Ida
Hiroyuki Ida
Background: To our knowledge, no rigorously designed clinical trials have evaluated the relation between vitamin D and physician-diagnosed seasonal i

1 January 2019 in Health Technology Assessment
Verified
Journal Article
Closed access
AMAdrian R Martineau
Adrian R Martineau
DJDavid Jolliffe
David Jolliffe
LGLauren Greenberg
Lauren Greenberg
JAJohn Aloia
John Aloia
PBPeter Bergman
Peter Bergman
RHRichard L Hooper
Richard L Hooper
Background: Randomised controlled trials (RCTs) exploring the potential of vitamin D to prevent acute respiratory infections have yielded mixed results. Individual participant data (IPD) meta-analysis has the potential to identify factors that may explain this heterogeneity. Objectives: To assess the overall effect of vitamin D supplementation on the risk of acute respiratory infections (ARIs) and to identify factors modifying this effect. Data sources: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, ClinicalTrials.gov and the International Standard Randomised Controlled Trials Number (ISRCTN) registry. Study selection: Randomised, double-blind, placebo-controlled trials of supplementation with vitamin D3 or vitamin D2 of any duration having incidence of acute respiratory infection as a prespecified efficacy outcome were selected. Study appraisal: Study quality was assessed using the Cochrane Collaboration Risk of Bias tool to assess sequence generation, allocation concealment, blinding of participants, personnel and outcome assessors, completeness of outcome data, evidence of selective outcome reporting and other potential threats to validity. Results: We identified 25 eligible RCTs (a total of 11,321 participants, aged from 0 to 95 years). IPD were obtained for 10,933 out of 11,321 (96.6%) participants. Vitamin D supplementation reduced the risk of ARI among all participants [adjusted odds ratio (aOR) 0.88, 95% confidence interval (CI) 0.81 to 0.96; heterogeneity p < 0.001]. Subgroup analysis revealed that protective effects were seen in individuals receiving daily or weekly vitamin D without additional bolus doses (aOR 0.81, 95% CI 0.72 to 0.91), but not in those receiving one or more bolus doses (aOR 0.97, 95% CI 0.86 to 1.10; p = 0.05). Among those receiving daily or weekly vitamin D, protective effects of vitamin D were stronger in individuals with a baseline 25-hydroxyvitamin D [25(OH)D] concentration of < 25 nmol/l (aOR 0.30, 95% CI 0.17 to 0.53) than in those with a baseline 25(OH)D concentration of ≥ 25 nmol/l (aOR 0.75, 95% CI 0.60 to 0.95; p = 0.006). Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (aOR 0.98, 95% CI 0.80 to 1.20; p = 0.83). The body of evidence contributing to these analyses was assessed as being of high quality. Limitations: Our study had limited power to detect the effects of vitamin D supplementation on the risk of upper versus lower respiratory infection, analysed separately. Conclusions: Vitamin D supplementation was safe, and it protected against ARIs overall. Very deficient individuals and those not receiving bolus doses experienced the benefit. Incorporation of additional IPD from ongoing trials in the field has the potential to increase statistical power for analyses of secondary outcomes. Study registration: This study is registered as PROSPERO CRD42014013953. Funding: The National Institute for Health Research Health Technology Assessment programme.

1 May 2013 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
MSMasahiko Suzuki
Masahiko Suzuki
MYMasayuki Yoshioka
Masayuki Yoshioka
MHMasaya Hashimoto
Masaya Hashimoto
MMMaiko Murakami
Maiko Murakami
MNMiki Noya
Miki Noya
Mitsuyoshi UrashimaMitsuyoshi Urashima
Mitsuyoshi Urashima
Background: In our previous study, higher serum 25-hydroxyvitamin D [25(OH)D] concentrations and the vitamin D receptor (VDR) FokI CC genotype were a

22 March 2004 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
HNH Nimura
H Nimura
NNN Narimiya
N Narimiya
NMN Mitsumori
N Mitsumori
YYY Yamazaki
Y Yamazaki
KYK Yanaga
K Yanaga
Mitsuyoshi UrashimaMitsuyoshi Urashima
Mitsuyoshi Urashima
Background: To avoid unnecessary lymphadenectomy in patients with cancer accurate diagnosis of the sentinel lymph node (SLN) is important. Methods: This report examined the initial clinical use of infrared ray electronic endoscopy (IREE) combined with indocyanine green (ICG) injection for SLN detection in 84 patients with gastric cancer not invading the subserosa (75 T1 N0 M0 and nine T2 N0 M0 tumours, according to tumour node metastasis classification). Results: There were no adverse events after injection of ICG. At least one SLN was detected in all but one patient by both ICG injection alone and by IREE with ICG. Eleven of the 84 patients had lymph node metastasis. SLNs detected by ICG injection alone did not include metastases in four of 11 patients, whereas IREE with ICG detected SLNs containing lymph node metastases in all 11 patients. Moreover, SLNs illuminated by IREE with ICG included all metastases among the 105 regional lymph nodes in the 11 patients; no metastatic lymph nodes were identified among 154 non-SLNs. Conclusion: IREE combined with ICG injection may efficiently detect SLNs that contain metastases in patients with gastric cancer.

1 December 2019 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
Mitsuyoshi UrashimaMitsuyoshi Urashima
Mitsuyoshi Urashima
HMHidetoshi Mezawa
Hidetoshi Mezawa
MOMai Okuyama
Mai Okuyama
TUTakashi Urashima
Takashi Urashima
DHDaishi Hirano
Daishi Hirano
HTHiroshi Tachimoto
Hiroshi Tachimoto
Food allergy mediated by IgE is becoming a global concern because its prevalence and severity are worsening.1-3 To overcome this issue, prolonged exclusive breastfeeding (BF) with or without supplementation with hypoallergenic formulas for infants at risk has been recommended.4 However, these preventive strategies have recently been called into question.5 For example, a cohort study6 demonstrated that the frequency of IgE-mediated cow’s milk allergy (CMA) was lower in infants who began receiving regular cow’s milk formula (CMF) within the first 14 days of life and therefore recommended CMF supplementation at birth. However, the effects of supplementing BF with CMF at birth or within the first 3 days of life on the risk of CMA7,8 and atopy9-11 are still controversial.

9 April 2019 in JAMA
Verified
Journal Article
Open access
PDF file
Mitsuyoshi UrashimaMitsuyoshi Urashima
Mitsuyoshi Urashima
HOHironori Ohdaira
Hironori Ohdaira
TATaisuke Akutsu
Taisuke Akutsu
SOShinya Okada
Shinya Okada
MYMasashi Yoshida
Masashi Yoshida
YSYutaka Suzuki
Yutaka Suzuki
Quiz Ref ID Serum levels of 25-hydroxyvitamin D (25[OH]D), a precursor of activated vitamin D, increase in response to exposure to sunlight, a vitamin D–rich diet, or vitamin D supplementation. Cancer cells are believed to take up and activate 25(OH)D within the cell, which binds to the vitamin D receptor to regulate gene expression and consequently suppresses cancer growth.1,2